Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

BioGaia, Audiocast with teleconference, Q3'24

By Inderes10/22/2024, 7:30 AM
BioGaia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Theresa Agnew
00:00 - 05:42

This is Theresa Agnew, CEO of BioGaia USA. I want to provide an overview of our results for Q3. First off, our sales were 304 million SEK, which was a decline of 4%, mainly due to weaker sales in EMEA as well as some order variability where we had higher orders in Q2 in certain markets. Sales in Europe, Middle East, Africa decreased by 27%, and in Asia Pacific, sales increased by 24%. And in the Americas we had an increase of 5%. There was good growth in Asia Pacific and also solid growth in the Americas. Our EBIT was 41 million SEK, which was a decline of 65%. This was primarily due to an impairment loss we had, which I will discuss. Our EBIT margin, because of that, was 14% without the impairment loss. If you look at the adjusted EBIT margin, it was 31% and the adjusted EBIT was 93 million, or a decline of 22%. So there were items that affected the comparability in the quarter. It was primarily an impairment loss attributed to our MetaboGen acquisition. And that impairment loss was 51.2 million SEK. I will talk a little about the clinical study that we conducted with prediabetes patients. So in terms of our launches, we had a number of launches: Pharax drops in Switzerland, Nescare B. Lactis in Brazil, and BioGaia Protectis drops with vitamin D in Mexico. BioGaia Prodentis lozenges were launched in a number of markets in Latin America, as well as BioGaia Protectis tablets with vitamin D in Peru, in addition to other key events. We announced in July our exclusive distribution agreement with Recordati in Italy. As you may know from previous discussions, Recordati was a sub-distributor and is now our exclusive distributor in Italy. On October 17th, we also announced preliminary results indicating that we would not meet market expectations. We had the impairment loss for the MetaboGen acquisition of 51.2 million SEK. This was due to a clinical study that had been ongoing for a number of years, where the primary endpoint for a potential product was not met. This product was focused on metabolic syndrome. So it was a clinical study with about 108 patients looking at glucose values over a 12-week period for people with prediabetes to see if glucose levels would decline with the probiotic versus the placebo. And unfortunately, we did not see the primary endpoint of reduction in glucose. We did have a secondary endpoint where we saw improvements in triglycerides, but our primary endpoints were not met. In terms of sales, as I said, we had an overall 4% decline for the quarter. Our pediatric sales decreased by 12%, mainly due to Protectis drops. And this was mainly in EMEA and the Americas. It was more about Brazil with the order phasing because we had a very high Q2 and then a lower Q3, and sales decreased in Turkey and Spain. Spain was another example where we had higher orders in Q2 and lower orders in Q3. Um, and the adult sales portfolio increased by 29%, mainly due to Prodentis and Protectis tablets. Our sales increased both in the US and in Korea with the Protectis tablets. Increased mainly in Indonesia and Hong Kong. And as you can see from a year-to-date standpoint, our pediatrics business is growing by 4%, and our adult business is growing by 16%. So overall growth of 6% and our pediatric business remains at around 78% of our overall sales. In terms of the regions I mentioned, the EMEA sales decreased by 27%. That was mainly due to Turkey, Spain, and Poland. In Asia Pacific, we had a healthy increase of 24%, mainly in Indonesia, China, and Australia. Australia is now one of our direct businesses, having transitioned to direct management in Q3. We have a promising start in both Australia and New Zealand. Our China business is performing very well, with increased orders in Q2 and continued higher orders in Q3. So, very strong growth in China. In the Americas, our sales increased by 5%, mainly driven by the US, Canada, and Guatemala. And I'm proud to say in the US and Canada, our business is growing very healthy, ahead of the market. So, as you see here then on the chart. Year to date, EMEA is declining 2%. Asia-Pacific is growing 25%, and the Americas are growing 4%. And it's good to see that our growth in the US is strong, even though we're still lapping the Gerber sales from last year, where they stopped selling our probiotic drops. And now I'll turn it over to Alex to go through the financials in more detail.

Alex
05:42 - 10:48

Thank you, Theresa. So to summarize the third quarter financials, we had revenues of $304 million, which was a 4% decline. Our operating profit was $41 million, which was a 65% decline, and our reported EBIT margin was 14%. Now, of course, there was this adjustment. So excluding the impairment loss, we had an EBIT of 93 million and an adjusted EBIT margin of 31%. Earnings per share were 0.366 and cash flow was 111 million SEK. If we look at the third quarter, then of the decline of 4% in the quarter, approximately 3% was due to currency effects, and organically we had a decline of 1.5%. And year to date we had an increase of 6%, of which organically there was a 7% increase and a negative currency effect of about 1%. If we look at the gross margin for the quarter, we had a gross margin of 73% versus 74%. In the same quarter last year in pediatrics, our margin was stable at 75%. In adults, the margin was slightly lower at 66% versus 68% one year ago. The main reason for the lower adult margin is mixed effects. For example, a larger proportion of sales of products where we have a slightly lower margin, and also due to some increased sales in certain markets. So, mixed effects is the explanation. And if you look year to date, we can see that in total we have a stable gross margin of 73%, which is the same as we had for the same period one year ago. We move on to the operating expenses. Our operating expenses increased by 56%. Again, this is due to the impairment loss. So, if we exclude that, we had an increase of operating expenses of 11%. If we look at the line items, sales and marketing costs increased due to increased activities related to sales and marketing. This is an effect of going direct. So basically, when we have increased activity levels in the direct markets, our costs will increase there, and therefore some marketing costs have also increased. So that is the main explanation that we conduct a larger proportion of our sales directly through our own subsidiaries. And therefore, those costs increase in terms of R&D. It's the impairment loss that is affecting the increase. If you exclude the impairment loss of 51 million, the R&D costs are essentially unchanged. Other operating expenses were minus 5 million. This is due to exchange losses. And in the same quarter last year, there was a slightly positive effect. And then in terms of admin costs, they are somewhat higher in the quarter, but in line with or actually lower than last year, year to date. So all in all, we have a total operating expense that increased by 11% on an adjusted basis. If you move on to the P&L, then to summarize, sales decreased by 4%. OpEx increased by 56%. And we have an EBIT margin of 14%. And on an adjusted basis, as I mentioned before, we have an EBIT margin of 31% versus 38% one year ago. And year to date, our adjusted EBIT margin is 35% compared to 36% one year ago. 36% and 35% are then above our financial target year to date. If we then look to summarize the cash flow. So cash flow from operating activities increased by 1% despite the lower operating profit, and this is due to changes in working capital, which are only minus four million. 4 million versus -23. One year ago. So, cash flow from operating activities is actually 1 million higher than last year. Even though we have a lower operating profit, cash flow from investing activities was very low—minus 3 million in the quarter. Cash flow from financing activities was actually a positive 14 million due to new share issues of about 20 million, which are included in that line item. And those new share issues are due to the incentive program from 2021. So all in all, we have a cash flow of 111 million versus 88 million one year ago. And the cash at the end of the period was 1.115 billion SEK. And with that, I hand over to Theresa Agnew for some concluding remarks.

Theresa Agnew
10:48 - 12:30

Yes. So overall, as we said, our net sales decreased by 4%, and it was a decrease of 2% excluding the currency effects. Our direct markets are performing strongly across all of them, but we have had a particularly strong start in Australia and New Zealand. Our EMEA sales decreased by 27%, mainly due to lower sales in the pediatric segment, primarily in markets such as Turkey, Spain, and Poland. In Asia Pacific, we continue our strong growth with 24%, which was due to higher sales in both the pediatric and adult segments. And mainly, we saw that growth in China. Indonesia and Australia. In the Americas, our sales increased modestly by 5%, mainly due to increased sales in the adult segment. We've seen that growth in dentists, Protectis as well as Gastrus sales, mainly increased in BioGaia USA, Canada as well as Guatemala in the quarter. As we said, we recorded an impairment loss, which is attributed to our MetaboGen acquisition of 51.2 million SEK. Our operating expenses increased by 56%, and if you exclude those items, the increase was 11%. Our EBIT margin was 14% and the adjusted margin was 31%. And we will continue to ramp up our investments to drive our continued growth. We have investments also in Q4 that we are primarily focusing on sales and marketing in our direct markets. Um, so I open it up for questions.

Operator
12:32 - 12:51

If you wish to ask a question, please dial pound five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound six on your telephone keypad. The next question comes from Matthias Waddeston from SEB. Please go ahead.

Unknown 1
12:56 - 13:25

Yes. Hello and thanks for taking my questions. The first one relates to EMEA. So Italy seems to be quite challenging. Wouldn't it be worthwhile to enter with your own brand there to build a strong long-term market? Because I understand it is quite a large market overall, and what makes you sort of confident in the setup that you have right now? That's the first one.

Theresa Agnew
13:25 - 14:28

Okay. In terms of confidence in the setup, we have a very strong partner, Recordati. Recordati is a top pharmaceutical company in Italy. We have just transitioned to them as our primary distributor. They are ramping up their efforts, intensifying their sales and marketing activities. We are helping them quite substantially in terms of training their sales organizations on our science. We are meeting with key opinion leaders and healthcare professionals to discuss our brand and our proprietary strains. So, we are confident in working with our new distributor partner that we will be able to drive growth in the Italian market in terms of our own brand. It's not something we're exploring right now. We have an exclusive distribution agreement with our partner, which is under the Ruffler brand. It is under the Recordati brand.

Unknown 1
14:32 - 15:00

Okay. Additionally, regarding EMEA, I believe there have been unsatisfactory growth rates in this market recently, say over the past 5 or 6 years. So maybe we could talk a little bit about the visibility in turning this market back into growth mode and sort of where you see untapped growth potential in EMEA. As it stands right now, and perhaps which countries in that respect would be highlighted?

Unknown 2
15:00 - 15:02

Yes, that's the second one.

Theresa Agnew
15:02 - 17:25

Yes. Good question. In terms of future growth, there are some markets where our business is smaller. Um, where we think there is upside in terms of the categories. For instance, in markets like Germany, we tend to see order variability with our distribution partner. But we're working with them on driving continuous growth in that market. We see a lot of penetration opportunity, as well as with our direct business in the UK. There is considerable upside in the UK. We actually just secured broad distribution of our BioGaia Protectis drops in Q3. Boots, which is the largest pharmacy chain in the UK, is very happy with the performance. Since we entered into their distribution in January of earlier this year. So now they've expanded our protective drops to 1200 stores. We also just introduced our protectors chewables into Boots in almost 600 stores, along with our dentists product, which is also available in nearly 600 Boots stores. So we see a big opportunity in the UK. Our Amazon business is growing strong, our Boots distribution is new, and we have a lot of opportunity there, as well as in the independent pharmacy channel where we ship to wholesalers. We see a lot of opportunity in the UK as well. I would also mention that we see opportunity in France, because 2023 was a lower year than previously. And so we see opportunities for growth next year with continued focus and ongoing marketing activities. We just launched our vitamin D drops in France, so that was a first where we'd only had our original protective drops. Now we have BioGaia Protectis drops with vitamin D, so we'll see how they perform in the French market. But it is quite successful in other European markets as well as markets in the Americas. So you know, we're focusing on the markets where we feel we have a lot of opportunity for growth. And the larger markets like Italy, France, Germany, and the UK.

Unknown 1
17:28 - 17:58

Thanks so much for that. And I will have the last question, then jump back to the queue, I think. Turning to operating expenses where you communicated this $7.35 million higher opex in the second half. Now, I think opex was up by quite a small amount, as you mentioned in the presentation. So, two questions. Do you see that as a smaller amount now for the second half? And also, do you expect it to spill over into 2025 as it stands right now? That's my last one.

Theresa Agnew
17:58 - 19:00

Yes. We did see some lower costs in Q3, but we also had some savings elsewhere in our portfolio. Our investments are in our direct businesses, and we're making investments in sales and marketing activities, which will continue into Q4. What we'll do is we are looking at the ROI of our investments. So we won't say right now what will continue into 2025, because we have to analyze and look at the return on the investment and then make decisions about what will be continued. Right now we are working on our global marketing campaign, which I've mentioned previously. So we will be investing in that, which is an exciting opportunity to do more advertising in some of our direct businesses to drive more brand awareness and brand consideration, and hence more penetration on our Protectis drops.

Unknown 1
19:04 - 19:05

Thank you.

Operator
19:11 - 19:17

The next question comes from Christopher Liljeberg from Carnegie Investment Bank. Please go ahead.

Unknown 3
19:19 - 19:32

Hi. Thank you and good morning. Um, some questions also focused on EMEA. So, first, you mentioned Poland here. Is that also facing effects or is there some underlying weakness?

Theresa Agnew
19:34 - 19:45

So, that was due to phasing effects. So we had a very high second quarter. So that was phasing for Q3. But overall for the year, you know, Poland is strongly performing.

Unknown 3
19:47 - 19:59

Okay. Good to hear that. And then coming back to Italy. So, when do you think realistically that you will be back growing sales in Italy again?

Theresa Agnew
20:00 - 20:39

So, you know, it will take time because we're training their sales force. They're going out more broadly to the medical community in terms of pediatricians, gastroenterologists, and key opinion leaders. So that will take time. I mean, I can't forecast a particular quarter. But we are starting to make some headway. Um, and, you know, we do have a very strong brand. LaFleur is a dominant brand in Italy. We just want to continue to drive the growth.

Unknown 3
20:43 - 20:47

Okay. What do you think, will you grow in Italy again in 2025?

Theresa Agnew
20:47 - 20:52

Yes. Yes, we do believe we will see growth in Italy again by 2025.

Unknown 3
20:53 - 21:21

Okay. And then I wonder about the situation in Turkey. I could understand your comment about demand, but there was something you wrote in the report that struck me. I think you said that inflation impacted the distributor's business operations. So does your distributor have some problems there, also impacting this more than the underlying demand?

Theresa Agnew
21:22 - 22:04

Turkey has been in a high inflationary environment for quite a while. Um, so with our distributor, they are a pharmaceutical company in Turkey. And so, what the inflationary environment has done is impacted consumer demand. Um, so it's just something we're paying a lot of attention to. We're working with our partner to help them as much as possible in terms of driving the marketing and sales. But it's just something where Turkey has become a little bit of a bigger impact in the quarter for us because of some of these negative impacts from the economy.

Unknown 3
22:07 - 22:13

Okay. So this issue has nothing to do with the partner. It's the underlying demand that's the problem.

Theresa Agnew
22:14 - 22:22

No, it doesn't have to do with the partner itself. It's more about the overall market in terms of what's impacting the demand.

Unknown 3
22:24 - 22:36

Okay. Thank you. And then my final question, it seems the strong momentum continues in the US. Could you provide some figures? How much are you growing in the U.S. right now? Maybe year to date? Just a rough figure.

Unknown 2
22:37 - 22:38

Sure.

Theresa Agnew
22:38 - 23:41

The US market is growing ahead of its competitors. So I would say it's in the high single digits. And what's doing extremely well is our Amazon business. So we are disproportionately growing in our Amazon business. Actually, we're having record months each year. I'm sorry, each month on Amazon. Amazon, as you know, is our main channel for distribution. But also positively impacting us is our distribution at Target, which is one of the major retailers in the United States. And they are very pleased with our business. And they've now expanded our Therax drops in another 800 stores. So it's a really strong distribution now in Target. So I would say, you know, the Amazon sales are positive. The target sales are positive. We also have strong growth on Walmart.com as well.

Unknown 3
23:45 - 23:47

Thank you. I'll get back to the question.

Theresa Agnew
23:47 - 23:51

And one thing also is, all of this is.

Operator
23:51 - 23:55

Comes from Matthias at Haggblom. Please go ahead.

Unknown 4
23:58 - 24:24

Yeah. Good morning. It wasn't clear to me how we should think about the phasing of the 75 to 85 million krona that you intended to deploy in the second half. So how much was taken in Q3? And what's left for Q4? And linked to this, when do you expect to see an impact from these initiatives in terms of sales growth? Is that already Q4 or more likely, Q1 and beyond?

Theresa Agnew
24:25 - 25:56

Um, so in terms of the spending. Um, so we look each quarter at what we're spending of the amount that we've signaled. We have spent in Q3, and we are continuing to spend in Q4. In terms of the impact on sales. Some of these investments are longer-term investments, so we won't see an immediate, positive impact in Q4, because we're investing in areas like sales activities, which take longer to build growth. They're very important in terms of our sustainable growth and our competitive advantage in the market, because they're part of our overarching medical marketing and sales strategy, directed towards healthcare professionals with our science and advantages. And actually, one of the things that we're seeing that is positively impacting our sales activities is that our protective tablets in the US have been experiencing increased growth as well. So, you know, we analyze our sales activities in the States and compare them to those states where we don't have sales activities. And so we're seeing positive growth of our products where we have increased our sales activities in those particular states in the United States. So we're seeing positive effects there on our drops as well as on our protective chewables now.

Unknown 4
26:00 - 26:19

Regarding the exact amount, since we quantified the intent to spend 75 to 85 million kroner, it's not possible to quantify what has been spent or confirm if that is still the intent for the second half. Just to help us understand how to think about operating expenses for the remainder of the year.

Alex
26:20 - 27:15

Um, yeah. Alex here. No, I can try to comment. I mean, we are spending the 75 to 85 million krona. I mean, since we communicated that figure, our sales, for example now in the third quarter, have been a bit weaker. And always, we try to adapt our costs to our revenues. So basically, we have made some savings compared to them. We're still pursuing these strategic activities and will continue to do so in the fourth quarter. I think our total spending will probably be a bit lower than that 75 to 85 at the moment due to the weaker sales we saw in the third quarter. And then you also have to remember that we typically spend more in the fourth quarter than in the third quarter in terms of our operating expenses, and it will be the same this year. So we will have higher costs in the fourth quarter compared to the third quarter. We are pursuing those strategic initiatives. We are doing those things. But all in all, the total effect will probably be slightly lower.

Unknown 4
27:18 - 27:29

That's clear. And then, secondly, can you expand on the competitive pressure in Italy that you mentioned? Is that derived from your previous distributor selling remaining stock under the previous brand, or is it linked to new entrants?

Theresa Agnew
27:30 - 27:52

It's not linked to new entrants. It's linked to current competitors in the market, but definitely also linked to our former distributor because our former distributor has their own brand of different probiotics, different strains in the market, but there are other competitors as well.

Unknown 2
27:56 - 27:57

Okay. And then finally.

Theresa Agnew
27:59 - 28:40

I was just going to make an additional comment. One good development is that we now have direct communication and an established relationship with Recordati, which is now our exclusive distributor. So our activities with that partner are enhanced because we're able to provide them with more marketing messages and support, as well as training for their sales organizations. And some of these things take time. But we feel like that support is even stronger than before. So we'll be able to have a competitive advantage against some of the current competitors in the market.

Unknown 4
28:43 - 29:02

That's clear. And then finally, when I look at consensus expectations for 2025 and 2026, it appears some forecasts suggest a depressed margin not only for 2024, but also for 2025 and 2026. So directionally, I don't expect you to quantify, but is there any way to think about the duration of this investment period?

Unknown 2
29:03 - 29:04

Yeah.

Theresa Agnew
29:04 - 29:47

So, we're looking at it right now for the second half of this year. So we're looking to see what the impact is. And as we said, some of the impact is longer term. So we have to look at trends. So we have to look at trends. What was the previous period, and what was the previous year? So we can look at the trends over time. Um, so we will continue to do our analysis. We're doing this weekly. We analyze our sales and their impacts on a monthly basis. Um, so, you know, if things are moving in the right direction, then we will continue investments. But for right now, we're just looking at the ROI of the investments that we're making.

Unknown 4
29:50 - 29:50

Thank you so much.

Operator
29:53 - 29:59

The next question comes from Christopher Liljeberg from Carnegie Investment Bank. Please go ahead.

Unknown 3
30:02 - 30:18

Okay, great. Three more questions. First, following up on Italy and what you said about the competition. So is the former partner still selling the Roy Turin brand or is it another product they are marketing?

Theresa Agnew
30:18 - 30:29

They are still selling the Royturin brand with different strains, so they are not selling our strains in the market.

Unknown 3
30:31 - 30:40

And have they been selling that product with different strains before, or did they just change the strain after you terminated the agreement?

Theresa Agnew
30:41 - 31:00

Um, they had launched a product prior to us terminating the agreement. They had launched a product with different strains. Um, so now they have also launched an additional product since then as well. So they have a number of drop products in the market as well as other formats.

Unknown 3
31:03 - 31:13

Okay. And they could do so because you had ended the previous agreement with them, correct?

Theresa Agnew
31:14 - 31:15

That's correct. So I.

Unknown 2
31:15 - 31:16

I guess that.

Unknown 3
31:16 - 31:28

Product wasn't that, I guess. This brand, if I remember correctly, was larger than the regular brands in Italy before.

Theresa Agnew
31:28 - 31:34

No, actually, ReFlor is the number one brand in the pediatric market.

Unknown 2
31:34 - 31:34

Okay.

Theresa Agnew
31:34 - 31:55

Okay. Area. So. Roy Turin. Roy Turin is much smaller. Okay. Additionally, there's also lower distribution in the pharmacies. You know, Floire is the number one and also has very broad distribution. So, they're growing from a smaller base, if you will.

Unknown 3
31:56 - 32:10

Okay. So, I guess the problem in Italy right now is that you haven't been able to retake this part of the market.

Theresa Agnew
32:13 - 32:17

Um, retake the part of the market. Um.

Unknown 2
32:17 - 32:18

Well.

Unknown 3
32:18 - 32:35

I mean, let's say, if we assume Reflower was, I don’t know, 20% of the sales. And I guess your ambition must be to regain that market share. Now, when you're not collaborating with the previous distributor.

Theresa Agnew
32:35 - 33:07

Yes, that is correct. So, because our product was previously available under the Roy Turin brand as a different SKU. Now our goal is to reclaim that business under the BioGaia brand, because previously, there were two different products in the market—our same product under two different brands. Okay. So now our goal is to take that market share now that the product is no longer available under Roy Turin.

Unknown 3
33:10 - 33:29

Yeah. Okay. That makes sense. Um, thanks. And then, could you comment on Australia? New Zealand. You said you were off to a good start here. Is it possible to comment on how much sales you had there in the quarter and whether that will increase in the coming quarters?

Theresa Agnew
33:30 - 34:18

Yes. I can't comment on the exact amount, but the sales we've had are higher than what we had previously. When you look at our sales to our former distributor, we anticipate that they will continue to increase because we're now driving our brand and also driving the overall category at retail. We have distribution in both retail and pharmacy channels. We also have distribution in one of the largest grocery store chains in Australia. So yes, we anticipate this to grow significantly. And also, we will be looking at bringing the rest of our product portfolio into the market as well.

Unknown 3
34:21 - 34:27

Did it have a meaningful impact on the strong growth rate in APAC in Q3?

Theresa Agnew
34:27 - 34:57

No, I would say not yet because it's so early. So basically, in Q3 we had what I would call pipe fill into pharmacies. The biggest impact was in China and Indonesia, markets like that, but I anticipate it will have a bigger impact as we go, especially as we start introducing products that haven't been in that market before, at least in the pharmacy channel. Okay.

Unknown 2
34:57 - 34:58

Thanks.

Unknown 3
34:59 - 35:15

Okay. And then, let me ask my final question about China. It seems to continue to do very well. Maybe you could just spend one or two minutes explaining your position in China?

Unknown 2
35:15 - 35:16

Yes.

Theresa Agnew
35:16 - 36:20

We are seeing very strong growth in China, and that is mainly in the online sales channel. That's where the majority of our sales are. We see our sales growth primarily in the general trade channel, though we also engage in cross-border trade. Our partner is conducting numerous events and marketing activities, driving significant focus on our brand through influencers, various channels, and live streaming to enhance awareness, trial, and consideration. We're very happy with the performance of our partner. And, you know, they really capitalize on these big events like Singles Day, where a lot of consumers are buying products and they end up disproportionately growing during those times. So they're doing a really good job of targeting the right consumers with the right messages to drive conversion.

Unknown 3
36:25 - 36:29

And, what are the big products in China?

Theresa Agnew
36:30 - 36:40

So, I mean, our biggest is Protectis drops. Um, that's our biggest by far. But we also have, you know, our Protectis Chewables as well.

Unknown 3
36:44 - 36:45

Okay. Thank you very much.

Operator
36:47 - 36:51

The next question comes from Matthias Waddesdon from CIB. Please, go ahead.

Unknown 1
36:54 - 37:21

Yes. Hi. Two follow-ups. Growth. I think the first one on growth. I think you mentioned that the year-to-date comp growth has been about 7%, and it looks a bit easier for the fourth quarter. So, is it reasonable to anticipate growth well within double-digit percentage for Q4, or are there reasons to be more cautious about the sales growth in Q4? That's the first one.

Theresa Agnew
37:22 - 38:10

Well, we don't really provide guidance quarter by quarter. In some of our regions, such as EMEA, we are continuing to focus on expanding our presence. Um, and we want to turn around some of those businesses that have been declining. Um, so that's probably where our biggest focus is for Q4. Um, also, you know, obviously we are continuing the growth in our direct markets, which has been very strong. So, we want to continue to see that growth in Q4. And our direct markets are where we are placing some of our investments. Hopefully, that gives you a sense of what to expect for Q4, but we do not provide specific guidance on numbers.

Unknown 1
38:13 - 38:17

Okay. And how much of the sales are in direct markets now?

Theresa Agnew
38:18 - 38:34

It's still around 30%. It's still around 30%. We anticipate that, now that we have Australia and New Zealand, these are smaller markets for us. It will continue. It will continue to grow for us. But right now, it's still around 30%.

Unknown 2
38:36 - 38:37

Good.

Unknown 1
38:37 - 38:52

And then the last one, for me, if you could highlight what major R&D project milestones you have coming in the next year or a couple of years that we should consider? That's my last one.

Theresa Agnew
38:53 - 40:32

Um, so in terms of milestones, you know, we look at it in two different ways. We look at new products and new product launches, as well as clinical studies. Um, so in terms of our new product launches. We are actually launching a new product this quarter. I won't discuss that yet because that will be covered in our Q4 report. We are currently launching a new product. And then we'll be rolling that out to more markets next year. We also have some exciting new product launches planned for next year in the oral health area. Um, and so, you know, I look at our pipeline, and we have a healthy pipeline of new products. The way our markets function, not all markets adopt new products simultaneously. So, you know, we phase out our new products because registration timings differ in each market. We are aiming to launch products earlier in some of our direct markets, provided that the registration requirements can be met. Um, and then in terms of clinical studies, we have an ongoing clinical study for our next generation collagen product. Um, so that is ongoing. And that is something that we'll look at milestones on, in the coming year and years. Um, so that’s exciting. And then we have 30 ongoing clinical studies, so we are always conducting clinical trials in various areas. But I would say one of the most exciting is around our next generation collagen product.

Unknown 1
40:35 - 40:50

Interesting. So what you said about launching a new product, should we expect you to launch new products in new areas, or how should we say? Areas of use, or.

Unknown 2
40:50 - 40:51

No, these.

Unknown 1
40:51 - 40:57

These tweaks to products are within current parameters. Uh. Yeah. Areas.

Theresa Agnew
40:57 - 41:16

Yeah. So the products I'm talking about for this year and next year, or this quarter and next year, are more what we call line extensions. So, they are new products in the areas where we operate at our core. Um, so in the gut health area, in the oral health area and so forth.

Unknown 1
41:18 - 41:20

That's fully clear. Thank you very much.

Operator
41:22 - 41:26

The next question comes from Matthias from Haggblom. Please go ahead.

Unknown 4
41:28 - 41:38

Yeah. Thank you very much. Just a follow-up here. So on the next generation colic product, is that the combination of the two strains that you referenced earlier this year?

Theresa Agnew
41:39 - 41:42

Yes, it is a combination of two strains. Yes.

Unknown 4
41:44 - 42:14

Okay. Because again, sticking to the publication earlier this year, I think in June, that you suggested you were bringing into clinical trials, I think it was also associated with some of the science within MetaboGen. So any read across from the failed trial in metabolic syndrome and impairment loss that you took in this quarter to the new combination trial, attempting to improve growth rates, if I understand correctly, or no read across at all?

Unknown 2
42:14 - 42:14

No.

Theresa Agnew
42:14 - 43:13

They are not connected at all. Um, actually, MetaboGen was focused specifically on metabolic syndrome. The clinical study we've been involved in over the last couple of years targeted people with prediabetes, aiming to observe if adding a probiotic results in a significant reduction in glucose levels, subsequently reducing what is called HbA1c, the primary measure for someone with diabetes or prediabetes. So this was specifically in patients with prediabetes where we did not see a difference versus placebo. In the primary endpoint. We did have a secondary endpoint, which was triglyceride improvement, where we did see a positive effect. Um, so the next generation colic product actually has nothing to do with MetaboGen. Um, it's a completely different health area of focus and completely different strains.

Unknown 4
43:16 - 43:23

And as a consequence, it is not linked to the BGL 47 strain that was part of the publication earlier this year.

Theresa Agnew
43:23 - 43:35

It is not linked to that. That is something else that we're looking at for the future. That is a Bifidobacterium strain. Um, so that would be a different potential new product in the future.

Unknown 4
43:38 - 43:39

That's awesome. Thank you very much.

Operator
43:41 - 43:47

There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Theresa Agnew
43:48 - 44:01

Thank you for your very good questions, as always. We appreciate it. And, um, thank you for listening to our overall Q3 results. Take care.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…